Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
A Study of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2019-02-05
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- Xin-Hua Xu
- Target Recruit Count
- 76
- Registration Number
- NCT03830411
- Locations
- 🇨🇳
Department of Medical Oncology, Central Hospital of Yichang City, the First Clinical Medical College of Three Gorges University, Yichang, Hubei, China
Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)
- Conditions
- Interventions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 761
- Registration Number
- NCT03829319
- Locations
- 🇺🇸
Thomas Jefferson University Hospital ( Site 0548), Philadelphia, Pennsylvania, United States
🇵🇱Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 0603), Warszawa, Mazowieckie, Poland
🇦🇷Sanatorio Parque ( Site 0365), Rosario, Santa Fe, Argentina
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
- Conditions
- Interventions
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 175
- Registration Number
- NCT03819465
- Locations
- 🇹🇭
Research Site, Hat Yai, Thailand
Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure
- Conditions
- Interventions
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 492
- Registration Number
- NCT03802240
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 826
- Registration Number
- NCT03800134
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-01-04
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 600
- Registration Number
- NCT03793179
- Locations
- 🇺🇸
Swedish Covenant Hospital, Chicago, Illinois, United States
🇺🇸University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Advocate Illinois Masonic Medical Center, Chicago, Illinois, United States
Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen
- Conditions
- Interventions
- First Posted Date
- 2019-01-03
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Xinqiao Hospital of Chongqing
- Registration Number
- NCT03792503
- Locations
- 🇨🇳
Xinqiao Hospital of Chongqing, Chongqing, China
Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer
- First Posted Date
- 2018-12-17
- Last Posted Date
- 2019-01-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 230
- Registration Number
- NCT03777124
An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease
- First Posted Date
- 2018-12-10
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT03770299
Anlotinib Plus Pemetrexed or Pemetrexed for Previously Untreated Elderly (>=70) or PS=2 Non-squamous NSCLC
- Conditions
- Interventions
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2018-12-07
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 106
- Registration Number
- NCT03768037
- Locations
- 🇨🇳
Beijing Chest Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.